Drug Profile
PF 6293620
Alternative Names: PF-06293620; PF-6293620; RN909Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antihyperglycaemics
- Mechanism of Action Glucagon receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in USA (IV, Injection)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in USA (SC, Injection)
- 01 Jan 2017 Pfizer completes a phase I trial in Type-2 diabetes mellitus in USA (SC) (IV) (NCT02211261)